Publication:
High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.

dc.contributor.authorPérez, Astrid
dc.contributor.authorGato, Eva
dc.contributor.authorPérez-Llarena, José
dc.contributor.authorFernández-Cuenca, Felipe
dc.contributor.authorGude, María José
dc.contributor.authorOviaño, Marina
dc.contributor.authorPachón, María Eugenia
dc.contributor.authorGarnacho, José
dc.contributor.authorGonzález, Verónica
dc.contributor.authorPascual, Álvaro
dc.contributor.authorCisneros, José Miguel
dc.contributor.authorBou, Germán
dc.date.accessioned2023-01-25T10:30:50Z
dc.date.available2023-01-25T10:30:50Z
dc.date.issued2019
dc.description.abstractTo characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains.
dc.identifier.doi10.1093/jac/dkz030
dc.identifier.essn1460-2091
dc.identifier.pmid30753505
dc.identifier.unpaywallURLhttps://academic.oup.com/jac/article-pdf/74/5/1244/28501149/dkz030.pdf
dc.identifier.urihttp://hdl.handle.net/10668/13554
dc.issue.number5
dc.journal.titleThe Journal of antimicrobial chemotherapy
dc.journal.titleabbreviationJ Antimicrob Chemother
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.number1244-1252
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subject.meshBacterial Proteins
dc.subject.meshDrug Resistance, Multiple, Bacterial
dc.subject.meshGreece
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshInhibitory Concentration 50
dc.subject.meshItaly
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshMolecular Epidemiology
dc.subject.meshMultilocus Sequence Typing
dc.subject.meshPhylogeny
dc.subject.meshPneumonia, Ventilator-Associated
dc.subject.meshPseudomonas Infections
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshSpain
dc.subject.meshbeta-Lactam Resistance
dc.subject.meshbeta-Lactamases
dc.titleHigh incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number74
dspace.entity.typePublication

Files